{"doi":"10.1183/13993003.00387-2017","title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","abstract":"<jats:p>Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and effectiveness of bedaquiline-containing regimens in a large, retrospective, observational study conducted in 25 centres and 15 countries in five continents.</jats:p><jats:p>428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDR-TB). MDR-TB cases were admitted to hospital for a median (interquartile range (IQR)) 179 (92–280) days and exposed to bedaquiline for 168 (86–180) days. Treatment regimens included, among others, linezolid, moxifloxacin, clofazimine and carbapenems (82.0%, 58.4%, 52.6% and 15.3% of cases, respectively).</jats:p><jats:p>Sputum smear and culture conversion rates in MDR-TB cases were 63.6% and 30.1%, respectively at 30 days, 81.1% and 56.7%, respectively at 60 days; 85.5% and 80.5%, respectively at 90 days and 88.7% and 91.2%, respectively at the end of treatment. The median (IQR) time to smear and culture conversion was 34 (30–60) days and 60 (33–90) days. Out of 247 culture-confirmed MDR-TB cases completing treatment, 71.3% achieved success (62.4% cured; 8.9% completed treatment), 13.4% died, 7.3% defaulted and 7.7% failed. Bedaquiline was interrupted due to adverse events in 5.8% of cases. A single case died, having electrocardiographic abnormalities that were probably non-bedaquiline related.</jats:p><jats:p>Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions.</jats:p>","journal":"European Respiratory Journal","year":2017,"id":608946,"datarank":14.330067189072981,"base_score":5.730099782973575,"endowment":5.730099782973575,"self_citation_contribution":0.8595149674460364,"citation_network_contribution":13.470552221626944,"self_endowment_contribution":0.8595149674460364,"citer_contribution":13.470552221626944,"corpus_percentile":null,"corpus_rank":null,"citation_count":307,"citer_count":200,"citers_with_citation_signal":173,"citers_with_endowment":173,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":528806,"name":"Keertan Dheda","orcid":"0000-0001-7709-5341","position":1,"is_corresponding":false},{"id":1564624,"name":"Martin Enwerem","orcid":null,"position":2,"is_corresponding":false},{"id":1564625,"name":"Rodolfo Romero Leyet","orcid":null,"position":3,"is_corresponding":false},{"id":1564626,"name":"Lia D'Ambrosio","orcid":null,"position":4,"is_corresponding":false},{"id":259182,"name":"Rosella Centis","orcid":"0000-0002-8551-3598","position":5,"is_corresponding":false},{"id":231946,"name":"Giovanni Sotgiu","orcid":"0000-0002-1600-4474","position":6,"is_corresponding":false},{"id":614651,"name":"Simon Tiberi","orcid":"0000-0001-9424-6551","position":7,"is_corresponding":false},{"id":1564627,"name":"Jan-Willem Alffenaar","orcid":null,"position":8,"is_corresponding":false},{"id":1564628,"name":"Andrey Maryandyshev","orcid":null,"position":9,"is_corresponding":false},{"id":1564629,"name":"Evgeny Belilovski","orcid":null,"position":10,"is_corresponding":false},{"id":245263,"name":"Shashank Ganatra","orcid":"0000-0002-1564-8198","position":11,"is_corresponding":false},{"id":817966,"name":"Alena Skrahina","orcid":"0000-0002-1460-0272","position":12,"is_corresponding":false},{"id":1564630,"name":"Onno Akkerman","orcid":null,"position":13,"is_corresponding":false},{"id":1564631,"name":"Alena Aleksa","orcid":null,"position":14,"is_corresponding":false},{"id":1564632,"name":"Rohit Amale","orcid":null,"position":15,"is_corresponding":false},{"id":1564633,"name":"Janina Artsukevich","orcid":null,"position":16,"is_corresponding":false},{"id":1564634,"name":"Judith Bruchfeld","orcid":null,"position":17,"is_corresponding":false},{"id":1564635,"name":"Jose A. Caminero","orcid":null,"position":18,"is_corresponding":false},{"id":1564636,"name":"Isabel Carpena Martinez","orcid":null,"position":19,"is_corresponding":false},{"id":1564637,"name":"Luigi Codecasa","orcid":null,"position":20,"is_corresponding":false},{"id":1564638,"name":"Margareth Dalcolmo","orcid":null,"position":21,"is_corresponding":false},{"id":1564639,"name":"Justin Denholm","orcid":null,"position":22,"is_corresponding":false},{"id":1564640,"name":"Paul Douglas","orcid":null,"position":23,"is_corresponding":false},{"id":64908,"name":"Raquel Duarte","orcid":"0000-0003-2257-3099","position":24,"is_corresponding":false},{"id":528805,"name":"Aliasgar Esmail","orcid":"0000-0002-1835-9252","position":25,"is_corresponding":false},{"id":1564641,"name":"Mohammed Fadul","orcid":null,"position":26,"is_corresponding":false},{"id":1564642,"name":"Alexey Filippov","orcid":null,"position":27,"is_corresponding":false},{"id":1564643,"name":"Lina Davies Forsman","orcid":null,"position":28,"is_corresponding":false},{"id":1201061,"name":"Mina Gaga","orcid":"0000-0002-9949-6012","position":29,"is_corresponding":false},{"id":1564644,"name":"Julia-Amaranta Garcia-Fuertes","orcid":null,"position":30,"is_corresponding":false},{"id":1564645,"name":"José-María García-García","orcid":"0000-0002-2809-6230","position":31,"is_corresponding":false},{"id":636247,"name":"Gina Gualano","orcid":"0000-0001-6149-0005","position":32,"is_corresponding":false},{"id":1564646,"name":"Jerker Jonsson","orcid":null,"position":33,"is_corresponding":false},{"id":1564647,"name":"Heinke Kunst","orcid":null,"position":34,"is_corresponding":false},{"id":1564648,"name":"Jillian S. Lau","orcid":null,"position":35,"is_corresponding":false},{"id":1564649,"name":"Barbara Lazaro Mastrapa","orcid":null,"position":36,"is_corresponding":false},{"id":1564650,"name":"Jorge Lazaro Teran Troya","orcid":null,"position":37,"is_corresponding":false},{"id":1564651,"name":"Selene Manga","orcid":null,"position":38,"is_corresponding":false},{"id":1564652,"name":"Katerina Manika","orcid":null,"position":39,"is_corresponding":false},{"id":1564653,"name":"Pablo González Montaner","orcid":null,"position":40,"is_corresponding":false},{"id":773212,"name":"Jai Mullerpattan","orcid":null,"position":41,"is_corresponding":false},{"id":614529,"name":"Suzette Oelofse","orcid":"0000-0001-7852-7804","position":42,"is_corresponding":false},{"id":1564654,"name":"Martina Ortelli","orcid":null,"position":43,"is_corresponding":false},{"id":1564655,"name":"Domingo Juan Palmero","orcid":null,"position":44,"is_corresponding":false},{"id":272460,"name":"Fabrizio Palmieri","orcid":"0000-0001-8184-6291","position":45,"is_corresponding":false},{"id":1564656,"name":"Antonella Papalia","orcid":null,"position":46,"is_corresponding":false},{"id":1564657,"name":"Apostolos Papavasileiou","orcid":null,"position":47,"is_corresponding":false},{"id":1564658,"name":"Marie-Christine Payen","orcid":null,"position":48,"is_corresponding":false},{"id":259200,"name":"Emanuele Pontali","orcid":"0000-0002-1085-0442","position":49,"is_corresponding":false},{"id":1564659,"name":"Carlos Robalo Cordeiro","orcid":null,"position":50,"is_corresponding":false},{"id":259201,"name":"Laura Saderi","orcid":"0000-0002-5131-9367","position":51,"is_corresponding":false},{"id":937677,"name":"Tsetan Dorji Sadutshang","orcid":null,"position":52,"is_corresponding":false},{"id":1564660,"name":"Tatsiana Sanukevich","orcid":null,"position":53,"is_corresponding":false},{"id":1564661,"name":"Varvara Solodovnikova","orcid":null,"position":54,"is_corresponding":false},{"id":259202,"name":"Antonio Spanevello","orcid":"0000-0002-3595-9903","position":55,"is_corresponding":false},{"id":937669,"name":"Sonam Topgyal","orcid":null,"position":56,"is_corresponding":false},{"id":256921,"name":"Federica Toscanini","orcid":null,"position":57,"is_corresponding":false},{"id":1564662,"name":"Adrian R. Tramontana","orcid":null,"position":58,"is_corresponding":false},{"id":1564663,"name":"Zarir Farokh Udwadia","orcid":null,"position":59,"is_corresponding":false},{"id":1564664,"name":"Pietro Viggiani","orcid":null,"position":60,"is_corresponding":false},{"id":1564665,"name":"Veronica White","orcid":null,"position":61,"is_corresponding":false},{"id":85550,"name":"Alimuddin Zumla","orcid":"0000-0002-5111-5735","position":62,"is_corresponding":false},{"id":259176,"name":"Giovanni Battista Migliori","orcid":"0000-0002-2597-574X","position":63,"is_corresponding":false},{"id":1564623,"name":"Sergey E. Borisov","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study","abstract":"<jats:p>Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and effectiveness of bedaquiline-containing regimens in a large, retrospective, observational study conducted in 25 centres and 15 countries in five continents.</jats:p><jats:p>428 culture-confirmed MDR-TB cases were analysed (61.5% male; 22.1% HIV-positive, 45.6% XDR-TB). MDR-TB cases were admitted to hospital for a median (interquartile range (IQR)) 179 (92–280) days and exposed to bedaquiline for 168 (86–180) days. Treatment regimens included, among others, linezolid, moxifloxacin, clofazimine and carbapenems (82.0%, 58.4%, 52.6% and 15.3% of cases, respectively).</jats:p><jats:p>Sputum smear and culture conversion rates in MDR-TB cases were 63.6% and 30.1%, respectively at 30 days, 81.1% and 56.7%, respectively at 60 days; 85.5% and 80.5%, respectively at 90 days and 88.7% and 91.2%, respectively at the end of treatment. The median (IQR) time to smear and culture conversion was 34 (30–60) days and 60 (33–90) days. Out of 247 culture-confirmed MDR-TB cases completing treatment, 71.3% achieved success (62.4% cured; 8.9% completed treatment), 13.4% died, 7.3% defaulted and 7.7% failed. Bedaquiline was interrupted due to adverse events in 5.8% of cases. A single case died, having electrocardiographic abnormalities that were probably non-bedaquiline related.</jats:p><jats:p>Bedaquiline-containing regimens achieved high conversion and success rates under different nonexperimental conditions.</jats:p>","is_dataset_classified":null,"base_score":5.730099782973575,"endowment":5.730099782973575,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28529205","pmcid":null,"openalex_id":"https://openalex.org/W2616064604","authors":[],"funders":[{"funder_name":"National Institute for Health Research (NIHR)","grant_id":"NF-SI-0616-10016","title":null}],"total_grants":1,"fwci":21.0761,"citation_percentile":0.99752925,"influential_citations":0,"citation_trend":[{"year":2017,"count":19},{"year":2018,"count":39},{"year":2019,"count":43},{"year":2020,"count":35},{"year":2021,"count":53},{"year":2022,"count":46},{"year":2023,"count":26},{"year":2024,"count":21},{"year":2025,"count":15},{"year":2026,"count":10}],"oa_status":"bronze","license":"other-oa","oa_locations":[{"url":"https://erj.ersjournals.com/content/erj/49/5/1700387.full.pdf","host_type":"journal"},{"url":"https://erj.ersjournals.com/content/erj/49/5/1700387.full.pdf","host_type":"publisher"},{"url":"https://syndication.highwire.org/content/doi/10.1183/13993003.00387-2017","host_type":"publisher"},{"url":"https://doi.org/10.1183/13993003.00387-2017","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28529205","host_type":"repository"},{"url":"https://research.rug.nl/en/publications/bebf70c8-c536-45cb-a5ee-35d486cc5652","host_type":"repository"},{"url":"http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/261774","host_type":"repository"},{"url":"https://discovery.ucl.ac.uk/id/eprint/10048890/","host_type":"repository"},{"url":"http://hdl.handle.net/11383/2069756","host_type":"repository"},{"url":"https://hdl.handle.net/11370/bebf70c8-c536-45cb-a5ee-35d486cc5652","host_type":"repository"},{"url":"http://qmro.qmul.ac.uk/xmlui/handle/123456789/36604","host_type":"repository"}],"fields_of_study":["Tuberculosis Research and Epidemiology","Diagnosis and treatment of tuberculosis","Infectious Diseases and Tuberculosis","Adult","Antitubercular Agents","Carbapenems","Clofazimine","Cohort Studies","Diarylquinolines","Drug Therapy, Combination","Extensively Drug-Resistant Tuberculosis","Female","HIV Infections","Humans","Linezolid","Male","Middle Aged","Patient Safety","Retrospective Studies","Sputum","Treatment Outcome","Tuberculosis, Multidrug-Resistant"],"mesh_terms":["Linezolid","Adult","Antitubercular Agents","Clofazimine","Drug Therapy, Combination","Female","Humans","Male","Middle Aged","Retrospective Studies","Sputum","Cohort Studies","HIV Infections","Carbapenems","Treatment Outcome","Tuberculosis, Multidrug-Resistant","Extensively Drug-Resistant Tuberculosis","Patient Safety","Diarylquinolines"],"keywords":["Medicine","Bedaquiline","Tuberculosis","Internal medicine","Mycobacterium tuberculosis","Pathology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-31T00:58:06.306875Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}